A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 24 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Colistimethate sodium (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- Acronyms PROMIS II
- Sponsors Zambon SpA
- 03 Apr 2018 Planned number of patients changed from 330 to 374.
- 03 Apr 2018 Planned End Date changed from 1 Oct 2019 to 1 Mar 2021.
- 03 Apr 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Mar 2021.